Showing 2441-2450 of 5771 results for "".
- Kala Pharmaceuticals Announces Dosing of First Patient in Phase 3 Trial for Dry Eye Disease Treatmenthttps://modernod.com/news/kala-pharmaceuticals-announces-dosing-of-first-patient-in-phase-3-stride-3-trial-of-kpi-121-0-25-in-patients-with-dry-eye-disease/2479973/Kala Pharmaceuticals announced that the first patient has been dosed in STRIDE 3 (Short Term Relief In Dry Eye), its phase 3 trial of KPI-121 0.25% for the short-term treatment of dry eye disease. “We are pleased to initiate the STRIDE 3 trial of KPI-121 0.25%. If approved, KPI-121 0.25% c
- EyePoint Pharmaceuticals Announces Presentation of Data Highlighting Yutiq for Posterior Segment Uveitishttps://modernod.com/news/eyepoint-pharmaceuticals-announces-presentation-of-data-highlighting-yutiq-for-posterior-segment-uveitis/2479984/EyePoint Pharmaceuticals announced the presentation of 12-month efficacy and safety data supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for noninfectious posterior segment uveitis. The data were presented at the American Society of R
- EyeGate Announces FDA Approval of Two IDE Submissions for Ocular Bandage Gelhttps://modernod.com/news/eyegate-announces-fda-approval-of-two-ide-submissions-for-ocular-bandage-gel/2479995/EyeGate Pharmaceuticals announced the FDA has approved two of EyeGate’s investigational device exemption (IDE) applications for pilot studies of the company’s Ocular Bandage Gel (OBG) product for the acceleration of reepithelialization of large corneal epithelial defects in patients having underg
- Heidelberg Engineering Announces Leadership Changeshttps://modernod.com/news/heidelberg-engineering-announces-leadership-changes/2480004/Heidelberg Engineering announced changes to the leadership team. Ali Tafreshi who has served in sales, marketing and research capacities in both the United States and German organizations
- Allergan and Molecular Partners Announce Positive Phase 3 Clinical Trials for Abicipar Pegol for the Treatment of Wet AMDhttps://modernod.com/news/allergan-and-molecular-partners-announce-positive-phase-3-clinical-trials-for-abicipar-pegol-for-the-treatment-of-wet-amd/2480008/Allergan and Molecular Partners announced the release of two positive clinical trials, SEQUOIA and CEDAR, for abicipar, demonstrating that both the 8-week and 12-week treatment regimens met the prespecified primary endpoint of noninferiority to ranibizumab. SEQUOIA and CEDAR are identical
- Ocular Therapeutix Announces FDA Acceptance of NDA Resubmission for Dextenzahttps://modernod.com/news/ocular-therapeutix-announces-fda-acceptance-of-nda-resubmission-for-dextenza/2480009/Ocular Therapeutix announced that it has received acknowledgement from the FDA that the new drug application (NDA) for Dextenza has been received. Dextenza (dexamethasone insert) 0.4 mg is Ocular Therapeutix’s lead product candidate for the treatment of ocular pain following ophthalmic surgery. T
- Lightmed Announces New Office Location in Caesarea, Israelhttps://modernod.com/news/lightmed-announces-new-office-location-in-caesarea-israel/2480027/Lightmed announced it has opened a new office location in Caesarea, Israel to expand its business and technological investments, and leverage Israel’s diverse and experienced medical technology talent pool. “Th
- Oyster Point Announces Positive Results from Phase 2 Clinical Trial of Investigational Treatment for Dry Eye Diseasehttps://modernod.com/news/oyster-point-pharma-announces-positive-results-from-phase-2-clinical-trial-of-investigational-treatment-for-dry-eye-disease/2480029/Oyster Point Pharma announced results from the PEARL study, a phase 2b clinical trial evaluating the company’s novel therapy for the treatment of dry eye disease (DED). The study met both sign and symptom primary endpoints by showing a statistically significant improvement in each compared to a v
- EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ for Posterior Segment Uveitis to be Presented at ASRShttps://modernod.com/news/eyepoint-pharmaceuticals-announces-data-highlighting-yutiq-for-posterior-segment-uveitis-to-be-presented-at-asrs/2480032/EyePoint Pharmaceuticals announced that three abstracts supporting the company’s YUTIQ (fluocinolone acetonide intravitreal implant) 3-year micro-insert for noninfectious posterior segment uveitis have been accepted for presentation at the 36th Annual Scientific Meeting of the American Soci
- Bausch + Lomb Announces FDA Filing Acceptance for Loteprednol Etabonate Ophthalmic Gelhttps://modernod.com/news/bausch-lomb-announces-fda-filing-acceptance-for-loteprednol-etabonate-ophthalmic-gel/2480037/Bausch + Lomb announced that the FDA has accepted the new drug application (NDA) for its sub-micron loteprednol etabonate ophthalmic gel 0.38%. The FDA has set a Prescription Drug User Fee Act (PDUFA) action date of February 25, 2019. If approved, the product would be the lowest concentrated lote